GlobalData on MSN6 小时
InnoCare Pharma receives approval for CLL/SLL combination therapy trial in China
China's National Medical Products Administration has approved a Phase III trial of InnoCare Pharma’s ICP-248 (Mesutoclax) ...
Oncology Nurse Advisor1 小时
Genetic Mutations Should Guide Optimal Treatment for Relapsed/Refractory CLL
In the subgroup with 17p deletion or TP53 mutation, zanubrutinib outperformed others with the most favorable HR (0.52) and the highest SUCRA value of 97%.